全文获取类型
收费全文 | 13992篇 |
免费 | 824篇 |
国内免费 | 1020篇 |
专业分类
耳鼻咽喉 | 512篇 |
儿科学 | 298篇 |
妇产科学 | 151篇 |
基础医学 | 1191篇 |
口腔科学 | 63篇 |
临床医学 | 1616篇 |
内科学 | 3364篇 |
皮肤病学 | 83篇 |
神经病学 | 350篇 |
特种医学 | 714篇 |
外科学 | 1936篇 |
综合类 | 1855篇 |
预防医学 | 690篇 |
眼科学 | 74篇 |
药学 | 1378篇 |
11篇 | |
中国医学 | 477篇 |
肿瘤学 | 1073篇 |
出版年
2023年 | 299篇 |
2022年 | 539篇 |
2021年 | 664篇 |
2020年 | 575篇 |
2019年 | 558篇 |
2018年 | 571篇 |
2017年 | 445篇 |
2016年 | 453篇 |
2015年 | 458篇 |
2014年 | 1079篇 |
2013年 | 1024篇 |
2012年 | 872篇 |
2011年 | 927篇 |
2010年 | 698篇 |
2009年 | 610篇 |
2008年 | 680篇 |
2007年 | 683篇 |
2006年 | 583篇 |
2005年 | 528篇 |
2004年 | 430篇 |
2003年 | 379篇 |
2002年 | 288篇 |
2001年 | 258篇 |
2000年 | 198篇 |
1999年 | 169篇 |
1998年 | 121篇 |
1997年 | 135篇 |
1996年 | 114篇 |
1995年 | 130篇 |
1994年 | 122篇 |
1993年 | 105篇 |
1992年 | 99篇 |
1991年 | 74篇 |
1990年 | 85篇 |
1989年 | 84篇 |
1988年 | 66篇 |
1987年 | 57篇 |
1986年 | 70篇 |
1985年 | 59篇 |
1984年 | 55篇 |
1983年 | 25篇 |
1982年 | 66篇 |
1981年 | 56篇 |
1980年 | 65篇 |
1979年 | 58篇 |
1978年 | 43篇 |
1977年 | 40篇 |
1976年 | 37篇 |
1975年 | 17篇 |
1973年 | 24篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的 临床观察白花蛇舌草干预湿热瘀滞型肠内多发息肉患者内镜治疗术后复发情况。方法 采用前瞻性的随机空白对照试验设计,选取2019年9月1日—2020年12月31日上海中医药大学附属普陀医院消化科收治的门诊及住院结直肠多发息肉患者132例作为研究对象。采用随机方法分为对照组和试验组,每组66例。对照组行内镜治疗术给予常规治疗后无药物干预,试验组在对照基础上给予白花蛇舌草汤剂(每日取白花蛇舌草15 g、大枣3枚,煎取400 mL汤剂,分2次饭后温服)治疗,连续干预1年。观察并比较两组术前与术后1年肠道内息肉的复发率、息肉数目、息肉最大直径、中医证候评分及肝肾功能及血常规的差异。结果 干预1年后,试验组复发9例(14.75%),对照组复发21例(33.33%),两组息肉复发率比较,差异有统计学意义(P<0.05)。试验组腺瘤、伴重度异型增生、体质量指数(BMI)≥24 kg·m-2患者治疗后息肉复发率均较对照组同类型降低,差异显著(P<0.05);术后1年试验组息肉最大直径及息肉数目均较对照组显著减小,差异显著(P<0.05);术后1年试验组中医证候各项评分均显著低于对照组(P<0.05);术后1年,两组中医证候疗效比较,差异具有统计学意义(P<0.05),且术前、术后1年两组患者肝肾功能、凝血功能等安全性指标无显著差异。结论 应用白花蛇舌草干预结直肠息肉术后患者,1年后明显降低肠内息肉的复发率,尤以腺瘤性息肉、重度异型增生、BMI超重患者更显著,不仅改善临床症状,还能有效预防结直肠息肉的复发,改善患者的预后。 相似文献
2.
《Digestive and liver disease》2022,54(11):1486-1493
BackgroundCold snare polypectomy (CSP) is a promising technique for the removal of sessile serrated polyps (SSPs) ≥ 10 mm. However, the efficacy and safety of this technique remain undetermined.AimsWe aimed to comprehensively evaluate the efficacy and safety of CSP for SSPs ≥ 10 mm.MethodsPubMed, EMBASE, Web of Science and Cochrane Library were searched up to January 2021.ResultsA total of 10 studies consisting of 1727 SSPs (range, 10–40 mm) from 1021 patients were included. The overall rates of technical success, adverse events (AEs) and residual SSPs were 100%, 0.7% and 2.9%, respectively. Subgroup analysis showed that the rates of technical success and AEs were comparable between CSP and cold endoscopic mucosal resection (EMR) (99.9% vs. 100% and 1.3% vs. 0.5%, respectively), between the proximal and distal colon (100% vs. 99.9% and 0.3% vs. 0, respectively), and between polyps of 10–19 mm and ≥20 mm (99.8% vs. 100% and 0.9% vs. 0, respectively). However, subgroup analysis showed that the rate of residual SSPs was slightly lower in CSP compared with cold EMR (1.3% vs. 3.9%), as well as in polyps of 10–19 mm compared with those ≥20 mm (3.1% vs. 4.7%).ConclusionCSP was an effective and safe technique for removing SSPs ≥ 10 mm. 相似文献
3.
《Journal of infection and chemotherapy》2022,28(4):548-553
IntroductionCOVID-19 patients have been reported to have digestive symptoms with poor outcome. Ivermectin, an antiparasitic drug, has been used in COVID-19 patients. The objective of this study was to evaluate whether ivermectin has effects on gastrointestinal complications and ventilator-free days in ventilated patients with COVID-19.MethodsCOVID-19 patients who were mechanically ventilated in the ICU were included in this study. The ventilated patients who received ivermectin within 3 days after admission were assigned to the Ivermectin group, and the others were assigned to the Control group. Patients in the Ivermectin group received ivermectin 200 μg/kg via nasal tube. The incidence of gastrointestinal complications and ventilator-free days within 4 weeks from admission were evaluated as clinical outcomes using a propensity score with the inverse probability weighting method.ResultsWe included 88 patients in this study, of whom 39 patients were classified into the Ivermectin group, and 49 patients were classified into the Control group. The hazard ratio for gastrointestinal complications in the Ivermectin group as compared with the Control group was 0.221 (95% confidence interval [CI], 0.057 to 0.855; p = 0.029) in a Cox proportional-hazard regression model. The odds ratio for ventilator-free days as compared with the Control group was 1.920 (95% CI, 1.076 to 3.425; p = 0.027) in a proportional odds logistic regression model.ConclusionsIvermectin improved gastrointestinal complications and the number of ventilator-free days in severe COVID-19 patients undergoing mechanical ventilation. Prevention of gastrointestinal symptoms by SARS-Cov-2 might be associated with COVID-19 outcome. 相似文献
4.
5.
6.
7.
《Pediatric clinics of North America》2015,62(6):1463-1477
8.
《Clinical gastroenterology and hepatology》2022,20(3):e380-e397
- Download : Download high-res image (232KB)
- Download : Download full-size image
9.
10.